Robin Kroll

ORCID: 0000-0002-8646-6092 · 4 papers in corpus
rct
Obstetrics and gynecology ·doi:10.1097/AOG.0000000000005380

OBJECTIVE: To evaluate the safety and efficacy of elagolix 150 mg once-daily monotherapy in patients with heavy menstrual bleeding associated with uterine leiomyomas. METHODS: A phase 4, randomized, double-blind, placebo-controlled, 6-mont…

rct 2024
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2024.06.040

BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic effects when used as monotherapy. Hormonal add-back therapy has the potential to mitigate these effects. OBJECTIVE:…

other 2021
Menopause (New York, N.Y.) ·doi:10.1097/gme.0000000000001793

OBJECTIVE: To determine prevalence and health-related quality of life (HRQOL) of moderate-to-severe vasomotor symptoms (VMS) in postmenopausal women in Europe, the US, and Japan, and among subgroups of women not taking hormone therapy (HT).…

2009
·doi:10.1016/j.fertnstert.2009.07.1100